-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Castle Biosciences, Lowers Price Target to $43

Benzinga·05/07/2026 11:32:02
Listen to the news
Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and lowers the price target from $44 to $43.